Back to Blog

Cannabis as a Potential Tool to Manage Opioid Cravings

The opioid epidemic has cast a long, dark shadow over public health, claiming countless lives and leaving communities devastated. As if the opioid crisis weren’t challenging enough, the emergence of unregulated opioids has exacerbated the situation, leading to a drug toxicity crisis.

In Ontario, construction workers are estimated to account for 30 to 50% of all opioid-related deaths1. Workers report the physical pain of their jobs as a reason for their drug use. According to a report by Public Health Ontario, 78% of overdose deaths had an injury or pain diagnosis prior to death (mainly fractures, dislocations, strains, or sprains, as well as low back pain2.

A recent study published in the journal of Drug Policy sheds light on the potential of cannabis to manage opioid cravings in people who are using unregulated opioids3.

Unregulated Opioids and Drug Toxicity Crisis

Unregulated opioids have infiltrated the illicit drug market, resulting in a surge of overdose cases and fatalities. As these synthetic opioids flood the streets, consumers are faced with dangerous threat due to their unpredictable potency and composition. Traditional harm reduction strategies, such as naloxone distribution and supervised consumption sites, struggle to keep up with the rapidly changing landscape of unregulated drugs. This is where cannabis steps into a new role – as a potential harm reduction tool.

Exploring the Cannabis-Opioid Connection: Insights from a New Study

The study published in Drug Policy delves into the intriguing relationship between cannabis and opioid use. It suggests that cannabis might play a role in managing opioid cravings, potentially providing a safer alternative for individuals entrenched in the unregulated opioid crisis. The researchers gather data from individuals with a history of opioid use who turned to cannabis for relief from withdrawal symptoms and cravings. The findings indicate “cannabis use to manage opioid cravings was reported by 118 (57.6%) participants. In the multivariable analysis, cannabis use to manage opioid cravings was significantly associated with self-reported reductions in opioid use.”3

The Mechanisms Behind the Connection

The study proposes several potential mechanisms through which cannabis might alleviate opioid cravings. One key mechanism is the interaction between cannabinoids found in cannabis and the endocannabinoid system (ECS) in the human body. The ECS plays a crucial role in regulating various physiological processes, including mood, pain, and appetite. By modulating the ECS, cannabis could potentially disrupt the reinforcing pathways associated with opioid cravings, providing consumers with a viable coping mechanism during withdrawal.

A Step Forward, Not a Panacea

It’s essential to view cannabis as a complementary approach rather than a panacea for the complex issue of opioid addiction. While the study’s findings are promising, they should serve as a starting point for further research and discussions among policymakers and healthcare professionals.


References: 
[1] Gomes, T. et al. Changing Circumstances Surrounding Opioid-Related Deaths in Ontario During the COVID-19 Pandemic. Ontario Drug Policy Research Network / The office of the Chief Coroner of Ontario / Ontario Forensic Pathology Service / Public Health Ontario. May 2021.
[2] Public Health Ontario. (2022). Construction workers disproportionately impacted by opioid-related deaths, report find. Retrieved from https://www.publichealthontario.ca/en/About/News/2022/Construction-workers-opioid-related-deaths
[3] Reddon, H., Lake, S., María Eugenia Socías, Hayashi, K., DeBeck, K., Walsh, Z., & Milloy, M-J. (2023). Cannabis use to manage opioid cravings among people who use unregulated opioids during a drug toxicity crisis. International Journal of Drug Policy, 119, 104113–104113. https://doi.org/10.1016/j.drugpo.2023.104113

Previous Article
'Keep Workers Working’ with Medicinal Cannabis: Unlocking the Potential of Paid Health Benefits!
Did you know one in five people suffer from chronic pain, which leaves many unable to work? Chronic pain is causing a significant burden in Canada. In 2019, the total cost of chronic pain reached over $40 billion, including health care costs and lost productivity. Health Canada projects that between 2019 and 2030, the number of people with chronic pain will rise by 17.5%, primarily because of population growth and aging. During this period, an increase in costs by 36% is anticipated.1 People living with pain in Canada face barriers to accessing care, employment support, and other essential services. Medicinal cannabis, when used responsibly and under medical supervision, has shown promise in enhancing the quality of life and fostering overall well-being.2 By offering this as a paid health benefit, a supportive environment is created where employees can focus on their professional endeavours minimizing disruptions stemming from health concerns. At Starseed, our aim is to 'Keep Workers Working,' which involves raising awareness about the potential benefits of medicinal cannabis to manage certain chronic conditions and enhance overall health. With the primary goal of reducing stigma, promoting education, and advocating for accessible medicinal cannabis. Integrating medicinal cannabis into a Company's health benefit plan provides employees with accessible and affordable treatment options. Recent research has also suggested access to medicinal cannabis through employee health benefits can have a positive impact on workplace attendance and productivity.3 When employees have access to effective pain management and stress relief, they are more likely to stay engaged, motivated, and committed to their roles, ultimately contributing to a more vibrant and successful work environment. What actions can be taken? As we champion medicinal cannabis coverage, let's work together with policymakers, HR professionals, and healthcare experts to ensure a progressive approach to medicinal cannabis coverage. At Starseed, we are committed to offering in-depth education about our medicinal cannabis program, with a responsible approach to its integration within a health benefit plan. For more information, please feel free to reach out to partners@starseed.com. Together, we can unlock the potential of medicinal cannabis to ‘Keep Workers Working’ and build a healthier, more resilient workforce for the future. References:  1 Canada, H. (2021, May 5). Canadian Pain Task Force Report: March 2021. Www.canada.ca. https://www.canada.ca/en/health-canada/corporate/about-health-canada/public-engagement/external-advisory-bodies/canadian-pain-task-force/report-2021.html 2 Arkell, T. R., Downey, L. A., Hayley, A. C., & Roth, S. (2023). Assessment of Medical Cannabis and Health-Related Quality of Life. JAMA Network Open, 6(5), e2312522. https://doi.org/10.1001/jamanetworkopen.2023.12522 3 Nicholas, L. H., & Maclean, J. C. (2019). THE EFFECT OF MEDICAL MARIJUANA LAWS ON THE HEALTH AND LABOR SUPPLY OF OLDER ADULTS: EVIDENCE FROM THE HEALTH AND RETIREMENT STUDY. Journal of Policy Analysis and Management. https://doi.org/10.1002/pam.22122
Next Article
Championing Medicinal Cannabis through our Patient Support Program
In 2018, the Canadian federal government committed to assessing the existing framework for medicinal cannabis. In support of this evaluation, the Medical Cannabis Access Survey (MCAS) was initiated, aiming to allow patients using medicinal cannabis to voice their challenges and offer suggestions for enhancing the future of the medical cannabis framework. The report highlights the challenges and underlines the need to advocate for medicinal cannabis as a paid health benefit. The findings from the Medical Cannabis Access Survey Summary Report, unveiled a startling discovery: only 6% of individuals received any form of coverage for medicinal cannabis expenses. This statistic underscores the significant financial strain experienced by patients in need of medicinal cannabis treatments. The report findings also concluded that almost 50% of individuals who had to stop taking their medicinal cannabis cited cost as the primary factor1. Accessibility to affordable healthcare is crucial as we advance in understanding the therapeutic potential and  it is imperative that we prioritize. Furthermore, the fact that 50% of individuals acquire medicinal cannabis from recreational sources, which lack authorization to offer medical advice, is a matter of substantial concern. Medicinal cannabis, like any other medication, should be under the guidance of a medical professional. These experts are trained to assess a patient’s condition, recommend appropriate dosages, and monitor its effects. When individuals resort to recreational sources, they forego the opportunity to receive personalized medical advice, which could lead to improper use, inadequate relief, or even potential health risks2. Starseed is the industry leader in medicinal cannabis and paid health benefits. Through collaborations with various unions and insurance partners, Starseed has advocated for the incorporation of paid health benefits related to medicinal cannabis for eligible beneficiaries. Central to this commitment is Starseed’s Patient Support Program, an initiative to enhance patient well-being. This comprehensive program includes evidence-based treatment approaches, patient education, prescription monitoring, and robust safeguards to ensure the safe and responsible utilization of cannabis. As advocates for patient-centered healthcare, we must work towards breaking down these barriers and ensuring patients have access to treatments that can improve their quality of life. Providing coverage for medicinal cannabis would alleviate the financial burden for patients and empower them to explore this viable treatment option. If you’re interested in delving deeper into the insights of the “Medical Cannabis Access Survey Summary Report,” find the full report here. For additional information on Starseed’s Patient Support Program or to learn more about medicinal cannabis as a paid health benefit,  please contact the Starseed team at partners@starseed.com. References: [1] Balneaves, L., Brown, A., Green, M., Prosk, E., Rapin, L., Monahan-Ellison, M., Mcmillan, E., Zaid, J., Dworkind, M., & Watling, C. (n.d.). Medical Cannabis Access and Experiences in Canada Medical Cannabis Access Survey Summary Report Developed collaboratively by. Retrieved August 15, 2023, from https://static1.squarespace.com/static/61cf68c3e7f7444a96b5c047/t/642c7d2fbde575503e411b4a/1680637234265/MCAS+Report+April+4+2023.pdf [2] Costiniuk, C. T., MacCallum, C. A., Boivin, M., Rueda, S., Lacasse, G., Walsh, Z., Daeninck, P. J., Margolese, S., Mandarino, E., Jagpaul Kaur Deol, Sanchez, T., & Bell, A. D. (2023). Why a distinct medical stream is necessary to support patients using cannabis for medical purposes. 5(1), 25–25. https://doi.org/10.1186/s42238-023-00195-8

Loading